FDA Authorizes At-Home Initiation of Alzheimer's Drug Leqembi

The FDA has approved a new subcutaneous starting regimen for Leqembi, an Alzheimer's treatment, allowing patients to begin therapy at home. This marks the first Alzheimer's drug that can be self-administered or given by a caregiver at the outset. The move aims to ease the treatment burden and broaden access for eligible individuals with early-stage Alzheimer's disease.